• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Adicet Bio, Inc. - Common Stock (NQ: ACET )

    0.9202 -0.0398 (-4.15%)
    Streaming Delayed Price Updated: 1:47 PM EST, Dec 27, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 183,128
    Open 0.9600
    Bid (Size) 0.9188 (9)
    Ask (Size) 0.9216 (8)
    Prev. Close 0.9600
    Today's Range 0.9069 - 0.9754
    52wk Range 0.8100 - 3.770
    Shares Outstanding 42,957,586
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
    From Adicet Bio, Inc.
    Via Business Wire
    Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer
    From Adicet Bio, Inc.
    Via Business Wire

    Performance

    YTD
    -54.22%
    -54.22%
    1 Month
    -4.18%
    -4.18%
    3 Month
    -34.27%
    -34.27%
    6 Month
    -31.33%
    -31.33%
    1 Year
    -47.72%
    -47.72%

    More News

    Read More
    Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
    From Adicet Bio, Inc.
    Via Business Wire
    Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
    From Adicet Bio, Inc.
    Via Business Wire
    Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases
    From Adicet Bio, Inc.
    Via Business Wire
    Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024
    From Adicet Bio, Inc.
    Via Business Wire
    Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates
    From Adicet Bio, Inc.
    Via Business Wire
    Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024
    From Adicet Bio, Inc.
    Via Business Wire
    Adicet Bio to Participate in Upcoming Investor Conferences
    From Adicet Bio, Inc.
    Via Business Wire
    Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From Adicet Bio, Inc.
    Via Business Wire
    Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome
    From Adicet Bio, Inc.
    Via Business Wire
    Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From Adicet Bio, Inc.
    Via Business Wire
    Adicet Bio to Present at the American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference
    From Adicet Bio, Inc.
    Via Business Wire
    Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases
    From Adicet Bio, Inc.
    Via Business Wire
    ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue
    From Adicet Bio, Inc.
    Via Business Wire
    This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
    Via Benzinga
    Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From Adicet Bio, Inc.
    Via Business Wire
    Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference
    From Adicet Bio, Inc.
    Via Business Wire
    Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors
    From Adicet Bio, Inc.
    Via Business Wire
    ACET Stock Earnings: Adicet Bio Beats EPS for Q2 2024
    Via InvestorPlace
    Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates
    From Adicet Bio, Inc.
    Via Business Wire
    Adicet Bio to Participate in Upcoming Investor Conferences
    From Adicet Bio, Inc.
    Via Business Wire
    Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From Adicet Bio, Inc.
    Via Business Wire
    Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
    From Adicet Bio, Inc.
    Via Business Wire
    Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From Adicet Bio, Inc.
    Via Business Wire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.